Hinge Health Inc. saw a 20.8% stock increase following renewed investor confidence in telehealth growth, driven by strategic acquisitions, partnerships, and strong financial performance. The company recently acquired a European competitor, partnered with a wearable tech firm, and reported $390M revenue with a 17.14M net income, positioning it as a leader in digital health solutions.

KeyCorp raised its target price for Hinge Health (NYSE:HNGE) from $45.00 to $60.00, with an overweight rating. Multiple analysts, including Evercore ISI, Royal Bank Of Canada, and Piper Sandler, initiated coverage or updated ratings for the company. Hinge Health's stock rose $0.55 to $48.19 on Monday, with a trading volume of 830,694 shares.

Citizens JMP initiated coverage on Hinge Health Inc (NYSE:HNGE) with a Market Outperform rating and a $58.00 price target, following the company's May 22 IPO at $32.00. Analysts including Truist, Raymond James, Needham, and Evercore ISI also issued positive ratings and price targets, citing Hinge Health's digital healthcare model and growth prospects.

Hinge Health's Relative Strength Rating (RSR) increased to 86, surpassing the 80 benchmark, indicating strong performance. The stock is on the IPO Leaders screen with a 43.80 buy point, while reporting 0% EPS growth and 50% sales growth. It ranks 9th in the Medical-Products industry.

KeyCorp released Q2 2025 earnings estimates for Hinge Health, projecting $0.09 per share with an "Overweight" rating and $45.00 price target. Other analysts, including Needham & Company, Barclays, William Blair, and Canaccord Genuity Group, also issued ratings and price targets. Hinge Health's stock rose 4.7% to $39.79, with 771,425 shares traded. The company describes itself as leveraging AI-driven software to transform healthcare outcomes.